



(51) International Patent Classification:

A61K 38/17 (2006.01) A61P 25/28 (2006.01)
C07K 14/47 (2006.01) A61P 3/10 (2006.01)
A61K 48/00 (2006.01) A61P 41/00 (2006.01)
C07K 16/40 (2006.01) A61P 13/12 (2006.01)
C12N 15/00 (2006.01)

(21) International Application Number:

PCT/EP2015/001294

(22) International Filing Date:

26 June 2015 (26.06.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2014/001736 26 June 2014 (26.06.2014) EP
PCT/EP2014/002724
8 October 2014 (08.10.2014) EP

(71) Applicant: XIGEN INFLAMMATION LTD. [CY/CY];
Arch. Makariou III, 195 Neocleous House, 3030 Limassol
(CY).

(72) Inventors: COMBETTE, Jean-Marc; 515, route de Ter-
ret, F-74140 Saint Cergues (FR). DELOCHE, Catherine;
22, Avenue William-Favre, CH-1207 Genf (CH).

(74) Agents: GRAF VON STOSCH, Andreas et al.; Graf von
Stosch, Patentanwalts-gesellschaft mbH, Prinzregenten-
strasse 22, 80538 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

25 February 2016

(54) Title: NEW USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY
FOR THE TREATMENT OF VARIOUS DISEASES

(57) Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the
protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as
pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.

